platinum-resistant recurrent ovarian cancer
Conditions
Interventions
A retrospective study, no interventions:None
Sponsors
Tongji Hospital Tongji Medical College of HUST
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) =18 years old at diagnosis of ovarian cancer. 2) Has histologically confirmed epithelial ovarian (including serous, endometrioid, mucinous, clear-cell, others), fallopian tube, or primary peritoneal carcinoma. 3) Has developed or develops platinum-resistant recurrent ovarian cancer (PRROC) (defined as physician assessed disease progression within 6 months after the last dose of platinum-based chemotherapy) between Jan 1,2020 and Dec 31, 2023. ? Note: the basis for physician assessment disease progression including symptoms, radiological and/or other imaging findings, CA-125 levels, physical examination, or others. 4) Receives initial chemotherapy after PRROC diagnosis between Jan 1,2020 and Dec 31, 2023. 5) Has treatment history record after initial diagnosis of ovarian cancer. 6) Has informed consent form (ICF) signed for the study or has conditions that are accepted by Institutional Review Board/Independent Ethics Committee (IRB/IEC) to waive ICF.
Exclusion criteria
Exclusion criteria: 1) Has participated in any investigational program/interventional clinical trial relating to PRROC interventions outside of routine clinical practice for anti-tumor purpose. 2) Has been treated with immunotherapy from diagnosis of ovarian cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To describe real-world chemotherapy treatment patterns of PRROC in China, focusing on the uptake of chemotherapy with or without non-chemotherapeutic agents.; | — |
Secondary
| Measure | Time frame |
|---|---|
| To describe chemotherapy treatment patterns across different subgroups, e.g., prior lines of systemic therapy (1, 2, =3), PFI (< 3 months vs 3-6 months);To describe the demographic and clinical characteristics of patients who receive chemotherapy as initial treatment after PRROC diagnosis in China;To identify demographic and clinical characteristics that might influence the choice between paclitaxel-based regimens vs. non-paclitaxel-based regimens;To describe the proportion of patients utilizing weekly paclitaxel vs. other dosing frequencies of paclitaxel;To describe the time to chemotherapy discontinuation and reasons for chemotherapy discontinuation; | — |
Countries
China
Contacts
Public ContactQinglei Gao
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology.
Outcome results
None listed